What Is The Current and Historic Market Size Analysis Of The Egrifta (Tesamorelin Acetate) Market?
The egrifta tesamorelin acetate market has seen considerable growth due to a variety of factors.
• In recent times, the market size for egrifta (tesamorelin acetate) has seen a steady rise, marked by a XX (HCAGR). It's predicted to scale up from $XX million in 2024, reaching $XX million in 2025, with a compound annual growth rate (CAGR) of XX%.
The historical phase witnessed this growth due to the increasing recognition of HIV-related complications, escalating demand for medicinal therapy, a rampant adoption of antiretroviral therapy, a steady emphasis on quality of life, strides in medical research, and enhanced awareness.
What Is The Forecast For The Egrifta (Tesamorelin Acetate) Market Size?
The egrifta tesamorelin acetate market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of egrifta (tesamorelin acetate) is forecasted to experience a compound annual growth rate (CAGR) of XX%, growing to $XX million by 2029.
This anticipated growth over the forecast period can be credited to an increasing number of chronic diseases, a surge in the number of hospitals, a growing demand for sophisticated body health monitoring tools, a rise in the occurrence of metabolic disorders, and an increasing awareness of disease treatment. Significant trends for the forecast period encompass an increased uptake of targeted therapies, integration into comprehensive care programs, expansion in personalized medicine, improved patient assistance schemes, and escalating research activities.
What Are The Essential Drivers Behind The Growth Of The Egrifta (Tesamorelin Acetate) Market?
The rising number of human immunodeficiency virus (HIV) instances is fuelling the expansion of the egrifta (tesamorelin acetate) sector. HIV cases denote scenarios where persons become infected with HIV, progressively depleting their immune capabilities. The escalation in HIV is partially attributed to a lack of knowledge and education about protective techniques, like the use of condoms and regular examinations, especially among groups with high risks. Egrifta instigates the discharge of a growth hormone that can reduce surplus visceral fat and enhance body composition, ultimately elevating the overall well-being and life quality for those with HIV. For example, based on the information from the Minnesota Department of Health, a health organization in the US, 324 new HIV diagnoses were reported in 2023, representing a 24% increase compared to 2022. Therefore, the surge in human immunodeficiency virus (HIV) instances is propelling the development of the egrifta (tesamorelin acetate) market.
How Is The Global Egrifta (Tesamorelin Acetate) Market Divided Into Key Segments?
The egrifta (tesamorelin acetate) market covered in this report is segmented –
1) By Clinical Indication: Human Immunodeficiency Virus (HIV)-Associated Lipodystrophy, Growth Hormone Deficiency, Abdominal Obesity, Metabolic Syndrome
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
3) By End-Users: Hospitals, Specialized Clinics, Home Care
Pre-Book The Egrifta (Tesamorelin Acetate) Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Egrifta (Tesamorelin Acetate) Market?
An important trend in the Egrifta (tesamorelin acetate) market is the commitment to the production of advanced synthetic peptide medicines that boost the efficacy of HIV-related lipodystrophy treatments. Synthetic peptide medications are purposefully created elements meant to provide designated therapeutic influences by replicating or augmenting the behaviour of natural peptides. For illustration, in December 2024, Theratechnologies Inc., a biopharmaceutical organization based in Canada, revealed that the manufacturing of EGRIFTA SV has restarted after a voluntary pause at its contract manufacturer's premises due to FDA inspection findings. A recently produced batch has passed quality control and will receive approval once the US Food and Drug Administration (FDA) approves a prior approval supplement, and an additional two batches are currently being manufactured. The firm is managing its inventory to ensure it can satisfy patient demand until mid-January 2025, and it is collaborating with the FDA to avoid a potential shortage in 2025. EGRIFTA SV is exclusively distributed in the United States.
Who Are the Key Players In The Egrifta (Tesamorelin Acetate) Market?
Major companies operating in the egrifta (tesamorelin acetate) market include:
• Theratechnologies Inc.
What Are The Regional Insights Into The Egrifta (Tesamorelin Acetate) Market?
North America was the largest region in the egrifta (tesamorelin acetate) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egrifta (tesamorelin acetate) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
